These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21267073)

  • 1. Influenza virus-like particles containing M2 induce broadly cross protective immunity.
    Song JM; Wang BZ; Park KM; Van Rooijen N; Quan FS; Kim MC; Jin HT; Pekosz A; Compans RW; Kang SM
    PLoS One; 2011 Jan; 6(1):e14538. PubMed ID: 21267073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
    Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
    Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.
    Kim MC; Song JM; O E; Kwon YM; Lee YJ; Compans RW; Kang SM
    Mol Ther; 2013 Feb; 21(2):485-92. PubMed ID: 23247101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
    Quan FS; Kim MC; Lee BJ; Song JM; Compans RW; Kang SM
    Virology; 2012 Sep; 430(2):127-35. PubMed ID: 22658901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.
    Soboleski MR; Gabbard JD; Price GE; Misplon JA; Lo CY; Perez DR; Ye J; Tompkins SM; Epstein SL
    PLoS One; 2011; 6(7):e21937. PubMed ID: 21789196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
    Music N; Reber AJ; Kim MC; York IA; Kang SM
    Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.
    Song JM; Van Rooijen N; Bozja J; Compans RW; Kang SM
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):757-61. PubMed ID: 21187388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.
    Kim MC; Lee JS; Kwon YM; O E; Lee YJ; Choi JG; Wang BZ; Compans RW; Kang SM
    Antiviral Res; 2013 Sep; 99(3):328-35. PubMed ID: 23811283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
    Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
    Kim MC; Lee YN; Ko EJ; Lee JS; Kwon YM; Hwang HS; Song JM; Song BM; Lee YJ; Choi JG; Kang HM; Quan FS; Compans RW; Kang SM
    Mol Ther; 2014 Jul; 22(7):1364-1374. PubMed ID: 24590045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.